Perinatal mortality · pregnant women at or near term with fetal cephalic presentations
It is very uncertain whether X‐ray pelvimetry changes perinatal mortality compared with no X‐ray pelvimetry (very low certainty).
1 finding from 1 review
Wound sepsis · pregnant women at or near term with fetal cephalic presentations
It is very uncertain whether X‐ray pelvimetry changes wound sepsis compared with no X‐ray pelvimetry (very low certainty).
1 finding from 1 review
Blood transfusion · pregnant women at or near term with fetal cephalic presentations
It is very uncertain whether X‐ray pelvimetry changes blood transfusion compared with no X‐ray pelvimetry (very low certainty).
1 finding from 1 review
Scar dehiscence · pregnant women at or near term with fetal cephalic presentations
It is very uncertain whether X‐ray pelvimetry changes scar dehiscence compared with no X‐ray pelvimetry (very low certainty).
1 finding from 1 review
Neonatal admission to special care · pregnant women at or near term with fetal cephalic presentations
It is very uncertain whether X‐ray pelvimetry changes admission to special care baby units compared with no X‐ray pelvimetry (very low certainty).
1 finding from 1 review
Apgar score less than 7 at 5 minutes · pregnant women at or near term with fetal cephalic presentations
1 finding from 1 review
Ulcer healing · people with diabetes and foot ulcers
The review found no eligible studies for this question.
2 findings from 1 review
Hysterectomy rate · endometrial hyperplasia
It is very uncertain whether summary of findings table ‐ Metformin changes hysterectomy rate compared with megestrol (very low certainty).
1 finding from 1 review
Abnormal uterine bleeding · endometrial hyperplasia
It is very uncertain whether summary of findings table ‐ Metformin changes abnormal uterine bleeding compared with megestrol (very low certainty).
1 finding from 1 review
HRQOL ‐ not measured · endometrial hyperplasia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects during treatment ‐ not reported · endometrial hyperplasia
The review found no eligible studies for this question.
1 finding from 1 review
Provision outcomes (prescription of testing or treatment, dichotomous) · outpatient health facilities
1 finding from 1 review
no estimate extracted
3 participants
Moderate
Provision outcomes (compliance with quality criteria, continuous) · outpatient health facilities
1 finding from 1 review
no estimate extracted
2 participants
Moderate
Health Service Utilisation · outpatient health facilities
1 finding from 1 review
no estimate extracted
3 participants
Low
Patient outcomes (dichotomous) · outpatient health facilities
1 finding from 1 review
no estimate extracted
1 participants
Low
Provider outcomes · outpatient health facilities
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Costs · outpatient health facilities
1 finding from 1 review
no estimate extracted
1 participants
Low
Adverse effects · outpatient health facilities
1 finding from 1 review
no estimate extracted
1 participants
Low
Fibroids · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance showed no clear difference in fibroids compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Abnormal Vaginal Bleeding or Spotting · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance probably leads to higher abnormal vaginal bleeding or spotting compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review